Creating Next Generation
Vaccines for Diseases
of Global Importance

Our Strength

Creating a new generation of adjuvanted subunit vaccines

We've been in business since 2018, focusing on one vaccine at a time.

Curevo Vaccine is a US-based, clinical-stage biotech company dedicated to developing next-generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market – quickly and efficiently. 

New adjuvant vaccines at Curevo 3372x5058
Hex 512x512
Hex 512x512
Shingles and Varicella at Curevo 272x362
Curevo Vaccine

Our Program

Herpes Zoster & Varicella

Curevo’s lead product, a sub-unit Herpes Zoster (Shingles) Vaccine, is in Phase II clinical trial (678 subjects). Results from our Phase I trial show a promising safety profile and the desired immune responses. Curevo’s vaccine has been developed for easy scale-up at different production sites to meet global demand.